Compare ANNX & CTLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | CTLP |
|---|---|---|
| Founded | 2011 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 730.4M | 798.9M |
| IPO Year | 2020 | N/A |
| Metric | ANNX | CTLP |
|---|---|---|
| Price | $5.38 | $10.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $16.11 |
| Revenue Next Year | N/A | $14.37 |
| P/E Ratio | ★ N/A | $13.69 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.29 | $7.01 |
| 52 Week High | $7.18 | $11.16 |
| Indicator | ANNX | CTLP |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 45.19 |
| Support Level | $4.65 | $9.82 |
| Resistance Level | $5.48 | $10.80 |
| Average True Range (ATR) | 0.31 | 0.23 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 57.67 | 59.02 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Cantaloupe Inc is a technology leader powering self-service commerce by offering one integrated solution for payments processing, logistics, and back-office management. The group offers a comprehensive suite of solutions, including micro-payment processing, self-checkout kiosks, mobile ordering, connected point-of-sale (POS) systems, and enterprise cloud software. Its product and services portfolio consists of Card Readers, Self-Service Kiosks, Smart Coolers, Seed Pick Easy, Cantaloupe Go, Cheq, Smart Lock Connect, and Vine Digital Studio. The company derives revenue streams from subscriptions, transaction processing, and equipment sales.